Active inflammation during pregnancy in women with inflammatory bowel disease (IBD) is a risk factor for clinical relapse. 1,2 In utero exposure to biologics is not associated with adverse pregnancy outcomes 3 or infections in infants born to mothers with IBD. 1,2,4 However, prior studies did not account for day care exposure in the first year of life, which is an established risk factor for infection in the general population. We aimed to determine whether children born to mothers with IBD have an increased rate of infection when attending day care in the first year after exposure to biologic therapy in utero.
- Day Care, Medical
- Inflammatory Bowel Diseases/complications
- Pregnancy Complications/drug therapy
- Prenatal Exposure Delayed Effects/drug therapy
ASJC Scopus subject areas